gc-1-compound has been researched along with Colorectal-Neoplasms* in 1 studies
1 other study(ies) available for gc-1-compound and Colorectal-Neoplasms
| Article | Year |
|---|---|
Selective thyroid hormone receptor beta agonist, GC-1, is capable to reduce growth of colorectal tumor in syngeneic mouse models.
The effect of thyroid hormone (TH) on cancers was proposed more than 100 years ago; however, conclusions are conflicting. THs are precisely regulated at tissue and cellular levels. It seems that this regulation is altered in cancers. Thyroid hormone receptor beta (TRβ) has anti-proliferative and tumor-suppressive effects in many cancer cells. Therefore, we decided to investigate thyroid hormone receptor beta (. Some concentrations of GC-1 had a marked negative effect on the cell viability of colorectal cell lines. Cell cycle analysis showed that the anti-proliferative effect of GC-1 may not result from cell cycle arrest or apoptosis. Tumor growth analysis in mice harboring colorectal tumor showed that GC-1 treatment for 8 d profoundly inhibited tumor growth and. Our results showed that specific activation of TRβ by GC-1 had negative effect on tumor growth and restored its gene expression in tumors of CRC mice model. Topics: Acetates; Animals; Colorectal Neoplasms; Disease Models, Animal; Fluorodeoxyglucose F18; Glucose; Mice; Phenols; Thyroid Hormone Receptors beta; Thyroid Hormones | 2022 |